Abstract
Abnormal processing and aggregation of synaptic proteins might play an important role in the pathogenesis of neurodegenerative disorders. Among them, amyloid precursor protein (APP) has been clearly associated with Alzheimer’s disease (AD) and various transgenic (tg) animal models have been developed where mutant APP is overexpressed under the regulatory control of neuronal promoters. These studies have shown that AD- like pathology (namely plaques and synapse damage) begins to develop at 6- 8 months of age in mice expressing human APP under Thyl, platelet-derived growth factor (B-chain) or protease-resistant prion protein promoters, provided that levels of APP are higher than 5–7 fold of endogenous levels. None of these models have shown the presence of tangles; however, tau- immunoreactive neurites in plaques and astroglial/microglial activation are observed after 12 months of age. Neuronal loss and alterations of synaptic function and connectivity are found in the CA1 region in the PDAPP tg mice lacking the Swiss Webster background. Co-expression of other genes associated with AD modify this phenotype, for example, mutant presenilin 1 accelerates the onset of plaque formation, transforming growth factor β enhances vascular amyloidosis, and apolipoprotein E decreases amyloid deposition. In conclusion, tg mice which are capable of mimicking some aspects of AD (provided that high enough levels of expression are achieved) can potentially be used to test novel drugs for the treatment of neurodegenerative disorders.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aguzzi A, Brandner S, Marino S, Steinbach JP (1996) Transgenic and knockout mice in the study of neurodegenerative diseases. J Mol Med 74: 111 – 126
Andra K, Abramowski D, Duke M, Probst A, Wiederholt KH, Burki K, Goedert M, Sommer B, Staufenbiel M (1996) Expression of APP in transgenic mice: a comparison of neuron-specific promoters. Neurobiol Aging 17: 183 – 190
Arai H, Lee V-Y, Messinger ML, Greenberg BD, Lowery DE, Trojanowski JQ (1991) Expression patterns of β-amyloid precursor protein (β-APP) in neural and nonneural tissues from Alzheimer’s disease and control subjects. Ann Neurol 30: 686 – 693
Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17: 263 – 264
Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D (1996) Familial Alzheimer’s disease-linked presenilin 1 variants elevate Aβ1-42/l-40 ratio in vitro and in vivo. Neuron 17: 1005 – 1013
Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19: 939 – 945
Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, Eckman C, Meiners J, Nilsen SP, Younkin SG, Hsiao KK (1997) Genetic modifications of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet 6: 1951 – 1959
Clark RF, Goate AM (1993) Molecular genetics of Alzheimer’s disease. Arch Neurol 50: 1164 – 1172
Cole GM, Masliah E, Huynh TV, DeTeresa R, Terry RD, Okudea C, Saitoh T (1989) An antiserum against amyloid β-protein precursor detects a unique peptide in Alzheimer brain. Neurosci Lett 100: 340-346 Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G (1991) Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. PNAS USA 88: 7552 – 7556
Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SC (1988) Alzheimer disease. A double immunohistochemical study of senile plaques. Am J Pathol 132: 86 – 101
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemes J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya- Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Alzheimer- type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373: 523 – 527
Games D, Masliah E, Lee M, Johnson-Wood K, Schenk D (1997) Neurodegenerative Alzheimer-like pathology in PDAPP 717V → F transgenic mice. In: Hyman BT, Duyckaerts C, Christen Y (eds) Connections, cognition and Alzheimer’s disease. Springer, Berlin Heidelberg New York Tokyo, pp 105 – 119
Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Guiffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Williamson R, Rossor M, Owen M, Hardy J (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349: 704
Hof PR, Cox K, Morrison JH (1990) Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer’s disease: I. Superior frontal and inferior temporal cortex. J Comp Neurol 301: 44 – 54
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders P, Zehr C, O’Campo K, Hardy J, Prada C-M, Eckman C. Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97 – 100
Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM (1999) Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer’s disease. J Clin Invest 103: R15 – R21
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 274: 99 – 102
Hyman BT, VanHoesen GW, Damasio AR, Barnes CL (1984) Alzheimer’s disease: Cell- specific pathology isolates the hippocampal formation. Science 225: 1168 – 1170
LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G (1995) The Alzheimer’s A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 9: 21 – 30
Martin LJ, Cork LC, Koo EH, Sisodia SS, Weidemann A, Beyreuther K, Masters C, Price DL (1989) Localization of amyloid precursor protein (APP) in brains of young and aged monkeys. Soc Neurosci Abstr 15: 23
Masliah E (1995) Mechanisms of synaptic dysfunction in Alzheimer’s disease. Histol Histopathol 10: 509 – 519
Masliah E, Mallory M, Hansen L, Alford M, Albright T, Terry R, Shapiro P, Sundsmo M, Saitoh T (1991) Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer disease. Acta Neuropathol 83: 12 – 20
Masliah E, Mallory M, Ge N, Saitoh T (1992) Amyloid precursor protein is localized in growing neurites of neonatal rat brain. Brain Res 593: 323 – 328
Masliah E, Mallory M, Hansen L, Alford M, DeTeresa R, Terry R (1993) An antibody against phosphorylated neurofilaments identifies a subset of damaged association axons in Alzheimer’s disease. Am J Pathol 142: 871 – 882
Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D (1996) Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer’s disease. J Neurosci 16: 5795 – 5811
Masters CL, Multhaup G, Simms G, Pottglesser J, Martins RN, Beyreuther K (1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4: 2757 – 2763
Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, van den Haute C, Checler F, Godaux E, Cordell B, Van Leuven F (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274: 6483– 6492
Mucke L, Yu G-Q, Abraham CR, McConlogue L, Rockenstein EM, Masliah E (1999) Potential role of alphal-antichymotrypsin and alpha-synuclein in Alzheimer’s disease pathogenesis assessed in bigenic mice expressin human amyloid precursor proteins. Soc Neurosci Abstr 25: 122. 10
Nalbantoglu J, Tirado-Santiago G, Lahsaini A, Poirier J, Goncalves O, Verge G, Momoli F, Welner SA, Massicotte G, Julien JP (1997) Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387: 500 – 505
Palmer AM, Gershon S (1990) Is the neuronal basis of Alzheimer’s disease cholinergic or glutamatergic? FASEB J 4: 2745 – 2752
Perry EK, Perry RH, Blessed G, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia: CAT and GAD activities in necropsy tissue. J Neurol Sci 34: 247 – 265
Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L (1995) Levels and alternative splicing of amyloid β protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer’s disease. J Biol Chem 270: 28257 – 28267
Rogers J, Luber-Narod J, Styren SD, Civin WH (1988) Expression of immune system- associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol Aging 9: 339 – 349
Selkoe DJ (1989) Amyloid β-protein precursor and the pathogenesis of Alzheimer’s disease. Cell 58: 611 – 612
Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (1990) Evidence that β- amyloid protein in Alzheimer’s disease is not derived by normal processing. Science 248: 492 – 494
Sturchler-Pierrat C, Abramowski D, Duke M, Wiederholt KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94: 13287 – 13292
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572 – 580
Terry RD, Hansen L, Masliah E (1994) Structural alterations in Alzheimer disease. In: Terry RD, Katzman R (eds), Alzheimer disease. Raven Press New York, pp 179 – 196
van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Keoyceau S, Ramdjielal R, Salehi A, Martens G, Grosveld FG, Peter J, Burbach H, Hoi EM (1998) Frameshift mutants of beta amyloid precursor protein and ubiqutin-B in Alzheimer’s and Down patients. Science 279: 242 – 247
Wilcock GK, Esiri MM, Bowen DM, Hughes AO (1988) The differential involvement of subcortical nuclei in senile dementia of Alzheimer’s type. J Neurol Neurosurg Psych 51: 842 – 849
Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Campagno F, Lin C, Samuels I, Mucke L (1997) Amyloidogenic role of transforming growth factor β1 in transgenic mice and Alzheimer’s disease. Nature 389: 603 – 606
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag
About this paper
Cite this paper
Masliah, E., Rockenstein, E. (2000). Genetically altered transgenic models of Alzheimer’s disease. In: Jellinger, K., Schmidt, R., Windisch, M. (eds) Advances in Dementia Research. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6781-6_20
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6781-6_20
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83512-8
Online ISBN: 978-3-7091-6781-6
eBook Packages: Springer Book Archive